Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.1% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares traded down 2.1% during mid-day trading on Thursday after an insider sold shares in the company. The company traded as low as $5.95 and last traded at $6.02. 1,935,999 shares were traded during trading, a decline of 67% from the average session volume of 5,807,483 shares. The stock had previously closed at $6.15.

Specifically, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total transaction of $94,800.00. Following the sale, the chief financial officer now directly owns 1,426,506 shares of the company’s stock, valued at $9,015,517.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,697,960.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

RXRX has been the topic of several analyst reports. Needham & Company LLC reduced their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Jefferies Financial Group dropped their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -4.14 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $6.69 and its 200 day moving average is $7.90.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s revenue was up 30.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.38) earnings per share. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Benjamin F. Edwards & Company Inc. acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth approximately $26,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. Amalgamated Bank grew its position in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals in the 3rd quarter valued at $69,000. Finally, Oxford Wealth Group LLC purchased a new position in Recursion Pharmaceuticals during the 1st quarter worth $106,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.